Treatment with Allogeneic Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome: A Double-Blind, Placebo-controlled, Multicenter Phase 2b Clinical Trial (STAT)
Rattachement africain : us, jp, de, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
RATIONALE: Prior clinical trials established the safety but not the efficacy of bone marrow-derived mesenchymal stromal cells (MSCs) in acute respiratory distress syndrome (ARDS). OBJECTIVES: To compare the efficacy of bone marrow-derived MSCs versus placebo in ARDS. METHODS: Prospective, double-blind, multicenter, randomized phase 2b clinical trial of one dose of intravenous MSCs (10 × 106/kg predicted body weight) versus placebo in 120 ventilated patients with ARDS (PaO2/FiO2 ratio <250 mm Hg). The primary endpoint was change in oxygenation index during the 36 hours after baseline. MEASUREMENTS AND MAIN RESULTS: Enrollment began in January 2020. Because of the coronavirus disease (COVID-19) pandemic, ARDS developed from COVID-19 in the majority of subjects (101 of 120; 84%). There were no significant baseline differences in severity of illness between patients treated with MSCs and those who received placebo in the entire cohort of 120 patients or in the 101 patients with COVID-19 ARDS. There were no differences in the primary endpoint of change in oxygenation index from baseline during the 36 hours after study product administration for the entire cohort or the COVID-19 subgroup, nor were there significant differences in mortality at 14, 28, 60, or 180 days. Plasma protein biomarker and gene expression analyses identified subgroups of patients with differential treatment responses in terms of clinical outcomes. CONCLUSIONS: This phase 2b clinical trial identified no physiologic or clinical benefit from a single dose of MSCs in patients with ARDS, including those with COVID-19 ARDS. In future trials, baseline plasma biological markers may help identify patients who are more likely to benefit from MSC therapy.Clinical trial registered with www. CLINICALTRIALS: gov (NCT03818854).
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Treatment with Allogeneic Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome: A Double-Blind, Placebo-controlled, Multicenter Phase 2b Clinical Trial (STAT)
- Date Crossref
- 29/07/2025
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of California pays non établi dans la noticeUniversité ou école supérieure
-
Cardiovascular Institute Hospital pays non établi dans la noticeÉtablissement de santé
-
University of San Francisco Cardiovascular Research Institute (CVRI) pays non établi dans la noticeUniversité ou école supérieure
-
University of California San Francisco Medical Center pays non établi dans la noticeÉtablissement de santé
-
San Francisco General Hospital Department of Surgery pays non établi dans la noticeÉtablissement de santé
-
Pulmonary and Critical Care Associates pays non établi dans la noticeÉtablissement de santé
-
Oregon Health & Science University pays non établi dans la noticeUniversité ou école supérieure
-
International Trauma Anesthesia and Critical Care Society pays non établi dans la noticeOrganisation à but non lucratif
-
University of Washington pays non établi dans la noticeUniversité ou école supérieure
-
University of Washington Applied Physics Laboratory pays non établi dans la noticeStructure de recherche
-
Harborview Medical Center and Sleep Medicine pays non établi dans la noticeÉtablissement de santé
-
Pediatrics and Genetics pays non établi dans la noticeÉtablissement de santé
University of California, Cardiovascular Institute Hospital et Cardiovascular Research Institute (CVRI) — University of San Francisco, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.